Preclinical Evaluation of Antimicrobial Nanodrugs

Translational medicine bridges the gap between research and clinical application of new discoveries by conducting preclinical evaluations to select active and least toxic compounds and predict clinical outcomes. Antimicrobial nanomedicines have higher specificity and can serve as adjuvants, but standardized protocols for evaluation are needed. This book discusses the fundamentals of robust, reproducible, and automatable evaluation platforms to discover new medicines for antimicrobial resistance.

Format: Paperback / softback
Length: 117 pages
Publication date: 09 May 2021
Publisher: Springer Nature Switzerland AG

Translational medicine plays a crucial role in bridging the gap between scientific discoveries and their practical application in healthcare. To ensure the efficient delivery of new drugs to care centers, a rigorous preclinical evaluation is essential. This evaluation involves both in vitro and in vivo testing to identify the most active and least toxic compounds, as well as to predict clinical outcomes.

One area of translational medicine that has gained significant attention is the use of antimicrobial nanomedicines. These nanomaterials have shown promising results in combating infectious diseases due to their higher specificity in targeting therapeutic targets and their ability to serve as adjuvants, enhancing the effectiveness of pre-existing immune compounds.

However, the design and development of standardized protocols for evaluating antimicrobial nanomedicines are urgently needed. These protocols should encompass laboratory activity, pharmacokinetic-pharmacodynamic and toxicokinetic behavior models, and a theranostics approach. They should also be capable of detecting promising formulations, diagnosing infectious diseases, and determining the appropriate treatment to implement personalized therapeutic behavior.

Given the vast potential of nanotechnology, neglecting to update screening platforms to incorporate new discoveries can hinder the correct application of these innovations. This can exacerbate the "valley of death" between innovations and their practical use, posing significant challenges to healthcare.

To address these challenges, this book is structured to discuss the fundamentals considered in designing robust, reproducible, and automatable evaluation platforms. These platforms are crucial in enabling the discovery of new medicines to combat antimicrobial resistance (RAM), one of the most pressing problems of our time.

By implementing these evaluation platforms, translational medicine can continue to advance and bring innovative solutions to the forefront of healthcare, improving patient outcomes and addressing the global healthcare crisis.

Weight: 454g
Dimension: 235 x 155 (mm)
ISBN-13: 9783030438579
Edition number: 1st ed. 2020